• Publications
  • Influence
Bone Morphogenetic Proteins Stimulate Angiogenesis through Osteoblast-Derived Vascular Endothelial Growth Factor A.
During bone formation and fracture healing there is a cross-talk between endothelial cells and osteoblasts. We previously showed that vascular endothelial growth factor A (VEGF-A) might be anExpand
  • 569
  • 14
  • PDF
High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer.
Metastatic progression of advanced prostate cancer is a major clinical problem. Identifying the cell(s) of origin in prostate cancer and its distant metastases may permit the development of moreExpand
  • 316
  • 13
  • PDF
Morphometric dimensions of the human sperm head depend on the staining method used.
BACKGROUND Assessment of sperm morphology (including morphometry) is extensively used to determine one of the qualities of a semen sample and depends on the differential staining of spermatozoa. AExpand
  • 110
  • 11
  • PDF
Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases.
Prostate and mammary cancer bone metastases can be osteoblastic or osteolytic, but the mechanisms determining these features are unclear. Bone morphogenetic and Wnt proteins are osteoinductiveExpand
  • 95
  • 9
Wnt but Not BMP Signaling Is Involved in the Inhibitory Action of Sclerostin on BMP‐Stimulated Bone Formation
Sclerostin is an osteocyte‐derived negative regulator of bone formation. It inhibits BMP‐stimulated bone formation both in vitro and in vivo but has no direct effect on BMP signaling. Instead,Expand
  • 249
  • 8
Epithelial Plasticity, Cancer Stem Cells, and the Tumor-Supportive Stroma in Bladder Carcinoma
High recurrence rates and poor survival rates of metastatic bladder cancer emphasize the need for a drug that can prevent and/or treat bladder cancer progression and metastasis formation.Expand
  • 138
  • 6
  • PDF
Bone morphogenetic protein 7: a broad-spectrum growth factor with multiple target therapeutic potency.
Bone morphogenetic protein 7 (BMP7) is a member of the transforming growth factor-β (TGF-β) superfamily of growth factors. In recent years, it has become clear that BMP7 is a very pleiotropic growthExpand
  • 69
  • 5
Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
Bone morphogenetic protein 7 (BMP7) counteracts the physiological epithelial-to-mesenchymal transition (EMT), a process that is indicative of epithelial plasticity. Because EMT is involved in cancer,Expand
  • 146
  • 4
  • PDF
Downregulation of Wnt Signaling by Increased Expression of Dickkopf‐1 and ‐2 is a Prerequisite for Late‐Stage Osteoblast Differentiation of KS483 Cells
We examined the role of Wnt/β‐catenin signaling in successive stages of osteoblast differentiation. It has been shown that Wnt signaling in mature osteoblasts needs to be downregulated to enable theExpand
  • 141
  • 3
BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo.
Bone morphogenic protein 7 (BMP7) counteracts physiological epithelial-to-mesenchymal transition, a process that is indicative of epithelial plasticity. Because epithelial-to-mesenchymal transitionExpand
  • 120
  • 3